Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2ZZ
|
|||
| Former ID |
DCL000525
|
|||
| Drug Name |
Esomeprazole magnesium + Aspirin
|
|||
| Indication | Peptic ulcer [ICD-11: DA61] | Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Streptococcus was increased by Esomeprazole (p = 0.044, q < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Actinobacteria
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Actinobacteria was increased by Esomeprazole. | |||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroidetes was increased by Esomeprazole. | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Firmicutes was increased by Esomeprazole. | |||
|
Studied Microbe: Proteobacteria
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Proteobacteria was increased by Esomeprazole. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric H(+)/K(+) ATPase alpha (ATP4A) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Oxidative phosphorylation | |||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Ion transport by P-type ATPases | |||
| WikiPathways | Iron uptake and transport | |||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90. | |||
| REF 2 | Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol. 2018 May;33(5):1059-1066. | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.